Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods, such as medicines and medical devices, available in Australia meet appropriate standards of quality, safety, and efficacy. This legislation was introduced to address the need for a robust regulatory framework governing the manufacturing, supply, and advertising of therapeutic goods to protect public health. The Act is administered by the Therapeutic Goods Administration (TGA), an agency within the Department of Health. The primary policy objective of the Act is to safeguard the health and safety of the Australian public by ensuring that therapeutic goods are of acceptable quality and that their benefits outweigh any risks associated with their use. In the context of this specific legislative instrument, the TGA, through its Delegate, Katherine Clark, has published details concerning the grant of Licences to Manufacture Therapeutic Goods to several entities. This action is in accordance with section 38 of the Therapeutic Goods Act 1989 and serves to officially recognise these manufacturers as meeting the necessary standards to produce therapeutic goods within Australia. By making this information publicly available, the TGA ensures transparency and accountability in the therapeutic goods industry, which is essential for maintaining public trust in the safety and quality of these products.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA), pertains to the regulation of therapeutic goods in Australia. Specifically, the Act covers a broad range of products including medicines, medical devices, blood, tissues, and other substances such as vitamins and complementary medicines. The Act applies to entities and individuals who manufacture, package, import, or otherwise supply therapeutic goods within Australia. It establishes licensing requirements to ensure that these goods meet necessary quality, safety, and efficacy standards. The geographic reach of the Act is national, extending to all states and territories of Australia, ensuring uniform regulation across the country. Exclusions under the Act include certain products such as tobacco products, which are regulated under different legislation, and some agricultural chemicals and industrial products that fall outside the definition of therapeutic goods. The Act allows for the extension of its application through subordinate instruments, which provide further details on specific regulatory requirements and enforcement mechanisms. This ensures the Act can adapt to new developments in therapeutic goods and technologies.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989 (the Act) relevant to the publication of the list of manufacturers granted a licence for the manufacture of therapeutic goods are sections 38 and 41A. Section 38 provides the legal basis for the Secretary of the Department of Health to grant a licence to an entity to manufacture therapeutic goods, while section 41A mandates the publication of details concerning the grant of such a licence. The document in question, signed by Katherine Clark on behalf of the Secretary, is a notification under section 41A that a licence has been granted to specific entities, namely Antaria Ltd, ChemCentre, and the National Institute of Complementary Medicine (paragraph 1). Entities granted a licence under section 38 of the Act are required to adhere to strict regulatory standards to ensure the safety, quality, and efficacy of the therapeutic goods they manufacture. These obligations include maintaining records of the manufacturing process, ensuring compliance with Good Manufacturing Practice (GMP) standards, and submitting regular reports to the Therapeutic Goods Administration (TGA). These entities must also ensure that their facilities and processes are inspected periodically by the TGA to verify adherence to regulatory requirements (paragraph 2). Breaches of the obligations under the Act can result in significant penalties and consequences. Under section 123 of the Act, an entity found to have contravened the Act, including failing to comply with manufacturing standards or providing false or misleading information, can face substantial fines. For a body corporate, the maximum penalty can be up to $5.5 million or three times the benefit obtained from the contravention, whichever is greater. Additionally, individuals who are officers of the corporation and are found to have been complicit in the contravention may also face personal fines and imprisonment, further emphasizing the seriousness with which the Act treats non-compliance (paragraph 3).